A proposed mitochondrial target for hydrogen changes the conversation

Edited by Samael A. Tejada, Founder & Editor-in-Chief

For years molecular hydrogen has been marketed as an antioxidant with no clear target. A new discovery changes the framing: the Rieske iron-sulfur protein (RISP) — a component of mitochondrial complex III — has emerged as a candidate molecular target for hydrogen. Clinician Dr. Jill Carnahan's August 31, 2026 review argues this reframes hydrogen as mitochondrial signal conditioning: a gentle stressor that prompts the cell's mitochondrial repair and quality-control programs, in the same conceptual family as sauna, zone-2 exercise and sulforaphane.

What does 'signal conditioning' mean here?

Instead of simply mopping up free radicals, hydrogen may act as a mild hormetic signal — nudging mitochondria to run their own cleanup and repair routines. If confirmed, that would move hydrogen from the antioxidant shelf into the stress-adaptation category.

What about regulation?

The review notes China has granted Class III medical device approval for a hydrogen inhalation device — a meaningful regulatory milestone, though device approval is not the same as proven clinical efficacy for any specific condition.

What is Carnahan's own caution?

She is explicit: human longevity data for hydrogen do not exist, and hydrogen should not substitute for established care. The target is a proposal, not a settled mechanism.

Where the evidence stands

• Preliminary: The Rieske iron-sulfur protein as a hydrogen target is a proposed mechanism requiring independent confirmation.
• Contested: Reframing hydrogen as 'signal conditioning' rather than an antioxidant is a clinical interpretation, not a settled consensus.
• Absent: Human longevity data for molecular hydrogen do not exist; clinical claims beyond the trial record exceed the evidence.